



NSI Meeting Announcement

Date: Thursday, Sept 20th, 12:15 – 13:00

Venue: Seminar room A3. 3067 Rikshospitalet,

Guest lecture

by

Dr. Anne Marie Rasmussen

“How to use T cells in immunotherapy for cancer”

Abstract

Adoptive T cell therapy is a form of cancer treatment based on infusion of ex vivo manipulated T cells with the goal to eliminate tumor cells and prevent relapse of the disease. Several different clinical trials have been conducted using adoptively transferred T cell or T cell subsets and therapeutic effects have been documented in several patients.

The challenge in cancer treatment is to break tolerance induced by the tumor and increase the number and avidity of T cells that can eliminate the tumor cells. By removing the T cells from the negative environment generated by the tumor and manipulating the cells ex vivo by introducing a signal through TcR and CD28, T cells become activated and are able to target tumor cells when re-injected into the patient.

Section for Immunotherapy and dept. for Cellular Therapy at the Radium hospital have developed a vaccination protocol using dendritic cells from cancer patients loaded with autologous tumor mRNA. This vaccine has been tested in more than 80 patients and in all trials immune responses were associated with improved clinical outcome but not durable remission. By combining a DC vaccination strategy with injection of ex vivo expanded tumor specific T cells we anticipate to improve the clinical outcome in these cancer patients.

In this presentation data from recent clinical trials using adoptive T cell therapy will be presented, including data from clinical trials planned for at DNR.

Refreshments will be served from 12:00

Welcome all!



Norwegian Society for Immunology
www.norwegianimmunology.org